Impact of Viral Infections on Blood Cell Development
Virus-induced Immunosuppression Via Infection of Hematopoietic Progenitors
This study is trying to see how HIV and COVID-19 affect the development of blood cells in both healthy people and those with HIV by looking at their bone marrow.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 45 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Assistance Publique - Hôpitaux de Paris Academic / other |
| Locations | 1 site (Boulogne-Billancourt) |
| Trial ID | NCT06458504 on ClinicalTrials.gov |
What this trial studies
This observational study aims to investigate how HIV-1 and SARS-CoV-2 affect hematopoietic stem and progenitor cells (HSPC) and their role in blood cell development. It will evaluate the susceptibility of HSPC to these viruses and assess the potential modulation of the bone marrow environment by infected cells. The study will involve both HIV-positive patients and healthy subjects undergoing bone marrow biopsies or myelograms at Ambroise Paré Hospital. The findings could provide insights into the mechanisms of virus-induced immunosuppression and its effects on hematopoiesis.
Who should consider this trial
Good fit: Ideal candidates include HIV-positive patients and healthy individuals undergoing bone marrow evaluations at Ambroise Paré Hospital.
Not a fit: Patients without any hematological concerns or those not managed at Ambroise Paré Hospital may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to better understanding and management of immunosuppression in patients with HIV and COVID-19.
How similar studies have performed: While studies have explored the effects of HIV on hematopoiesis, the specific investigation of SARS-CoV-2's impact on HSPC is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: HIV patients : * HIV-positive patients with a negative or positive viral load. * managed at Ambroise Paré Hospital. * patients with a bone marrow biopsy or myelogram performed as part of their care. Healthy subjects without HIV - patients with a BM biopsy or myelogram performed as part of their care for a suspected hematological pathology. Management at Ambroise Paré Hospital. Exclusion Criteria: \-
Where this trial is running
Boulogne-Billancourt
- Hematology and interne medicine department, Ambroise Paré hospital - APHP — Boulogne-Billancourt, France (Recruiting)
Study contacts
- Principal investigator: Claude CAPRON, MD, PhD — Laboratory of Immunology, Ambroise Paré hospital - APHP
- Study coordinator: Claude CAPRON, MD, PhD
- Email: claude.capron@aphp.fr
- Phone: + 33 01 49 09 58 47
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.